Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced
“This positive safety review marks an important milestone in the development of our allogeneic gamma delta platform, building on the strong safety profile that we previously established for our novel therapeutic,” said Bryan Kobel, Chief Executive Officer of TC BioPharm. “We expect the trial to enroll well in 2024, as we believe there is a high degree of interest in our therapeutic and a growing recognition of the role gamma deltas play in the fight against cancer. We will begin redosing in ACHIEVE based on the compelling existing therapeutic profile. While the process has been relatively slow getting to this point in ACHIEVE, we believe those headwinds to have subsided and been addressed by our team and we look forward to a more rapid open enrollment throughout 2024 now that the safety portion of the trial is complete.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data